Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic amyloid-beta oligomers by McHale-Owen, H & Bate, C
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the peer-reviewed, manuscript version of an article published in Biochimica et Biophysica 
Acta (BBA) - Molecular Basis of Disease. The version of record is available from the journal site: 
https://doi.org/10.1016/j.bbadis.2017.12.017.  
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/. 
The full details of the published version of the article are as follows: 
 
TITLE: Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic amyloid-β 
oligomers 
AUTHORS: Harriet McHale-Owen, Clive Bate 
JOURNAL: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 
PUBLISHER:  Elsevier  
PUBLICATION DATE: March 2018  
DOI: 10.1016/j.bbadis.2017.12.017 
1 
 
Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic 
amyloid-β oligomers 
 
Harriet McHale-Owen & Clive Bate  
 
Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, 
North Mymms, Herts, AL9 7TA. 
 
Corresponding Author; Dr Clive Bate, Tel: 01707 666550, Fax 01707 661464, E-mail: cbate@rvc.ac.uk 
 
Abstract 
 
The production of amyloid-β (Aβ) is the key factor driving pathogenesis in Alzheimer’s disease (AD). 
Increasing concentrations of Aβ within the brain cause synapse degeneration and the dementia that is 
characteristic of AD. Here the factors that affect the release of disease-relevant forms Aβ were studied in a 
cell model. 7PA2 cells expressing the human amyloid precursor protein released soluble Aβ oligomers that 
caused synapse damage in cultured neurons. Supernatants from 7PA2 cells treated with the cholesterol 
synthesis inhibitor squalestatin contained similar concentrations of Aβ42 to control cells but did not cause 
synapse damage in neuronal cultures. These supernatants contained reduced concentrations of Aβ42 
oligomers and increased concentrations of Aβ42 monomers. Treatment of 7PA2 cells with platelet-activating 
factor (PAF) antagonists had similar effects; it reduced concentrations of Aβ42 oligomers and increased 
concentrations of Aβ42 monomers in cell supernatants. PAF activated cholesterol ester hydrolases (CEH), 
enzymes that released cholesterol from stores of cholesterol esters. Inhibition of CEH also reduced 
concentrations of Aβ42 oligomers and increased concentrations of Aβ42 monomers in cell supernatants. The 
Aβ monomers produced by treated cells protected neurons against Aβ oligomer-induced synapse damage. 
These studies indicate that pharmacological manipulation of cells can alter the ratio of Aβ 
monomer:oligomer released and consequently their effects on synapses.  
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1. Introduction 
 
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia as a 
consequence of synaptic failure (1,2). The amyloid hypothesis maintains that the pivotal event in AD is the 
production of toxic amyloid-β (Aβ) peptides following the proteolytic cleavage of the amyloid precursor 
protein (APP) (3). In animal models intracerebral injections of Aβ peptides caused synapse damage and 
impaired memory formation (4,5). Neurodegeneration is not directly proportional to concentrations of Aβ; 
rather that it is dependent upon numerous factors including the state of Aβ aggregation and specific Aβ 
conformations. Perhaps the key to understanding the amyloid hypothesis is the realization that there exist 
conformational forms of disease-relevant Aβ, while other conformations are less toxic or even biologically 
inert. Therefore, we sought to identify factors that specifically affected the release of toxic forms of Aβ. 
Chinese hamster ovary (CHO) cells stably transfected with cDNA encoding the human (APP)751, known as 
7PA2 cells, have been extensively used as they release soluble Aβ (6,7) that have similar properties to the 
soluble Aβ species found within the brains of AD patients (8-11).  
 
The loss of synaptic proteins such as synaptophysin from the brain is indicative of synapse degeneration 
and provided a good correlate of the degree of dementia in AD (12-14). Consequently, the loss of synaptic 
proteins from cultured primary neurons incubated with Aβ provides a useful in vitro model in which to 
investigate AD-related synapse damage (15). Synapse density in cultured neurons was measured by 
quantification of the amounts of synaptophysin and cysteine string protein (CSP) (15). Picomolar 
concentrations of soluble Aβ caused the loss of synaptophysin and CSP from cultured neurons (15) and 
impaired memory formation in animal models (10,16).  
 
Although many studies implicate cholesterol concentrations as a major factor that regulates Aβ production, 
as reviewed by Chang and colleagues (17), the effects of cholesterol depletion on Aβ production remain 
controversial. While initial studies demonstrated that cholesterol depletion reduced the production of Aβ 
(18), another study reported it increased Aβ concentrations (19). However, the conventional cholesterol 
synthesis inhibitors (3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) used to deplete cells 
of cholesterol also block the production of isoprenoids, which also affect Aβ concentrations (20,21). 
Consequently it is not clear whether the effects of 
these drugs on Aβ concentrations are mediated by their 
effects upon cholesterol, or upon isoprenoid 
concentrations. In addition, previous studies have not differentiated the effects of cholesterol depletion upon 
the type of Aβ produced (toxic/non-toxic). 
Abbreviations – Alzheimer’s Disease (AD), 
amyloid-β (Aβ), amyloid precursor protein (APP), 
arachidonyl trifluoromethyl ketone (AACOCF3), 
Chinese hamster ovary (CHO), cholesterol ester 
hydrolase (CEH) conditioned media (CM), 
cholesteryl N-(2-dimethylaminoethyl) 
carbamate (c-carbamat ), cystei e string protein 
(CSP), diethylumbelliferyl phosphate (DEUP), 
endoplasmic reticulum (ER), 1-O-Hexadecyl-2-
acetyl-sn-glycerol-3-phospho-(N,N,N-
trimethyl)-hexanolamine (Hexa-PAF), methyl 
arachidonyl fluorophosphonate (MAFP), 
phospholipase A2 (PLA2), platelet-activating 
factor (PAF), standard deviation (SD) 
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Here we show that treatment of 7PA2 cells with squalestatin, a squalene synthetase inhibitor that inhibits 
cholesterol synthesis without affecting the production of isoprenoids (22), reduced the release of 
synaptotoxic Aβ; conditioned media (CM) from these cells did not cause synapse degeneration when added 
to cultured neurons. Surprisingly, squalestatin had only a small affect upon the total concentrations of Aβ42 
in CM, rather it changed the ratio of Aβ oligomers to Aβ monomers. Treatment reduced concentrations of 
the synaptotoxic Aβ oligomers and increased concentrations of neuroprotective Aβ monomers (23). This 
study also identified other drugs that affected the type of Aβ released; the release of soluble Aβ oligomers 
was reduced by treating 7PA2 cells with either phospholipase A2 (PLA2) inhibitors, platelet-activating 
factor (PAF) antagonists or cholesterol ester hydrolase (CEH) inhibitors. The observation that PAF 
activated CEHs, resulting in increased cholesterol concentrations within the endoplasmic reticulum (ER), 
led to the hypothesis that PAF-induced activation of CEH releases cholesterol that consequently affected 
the production of Aβ oligomers. 
 
2. Methods 
 
2.1. Culture of 7PA2 cells – Chinese hamster ovary (CHO) cells stably transfected with cDNA encoding 
APP751 (referred to as 7PA2 cells) originated from Professor E Koo’s laboratory (National University of 
Singapore) were grown in Dulbecco’s minimum essential medium supplemented with 10% foetal calf 
serum as described (6). For experiments 7PA2 cells were grown in 6 well plates until 80% confluent. 
Culture media was replaced with neurobasal medium containing B27 components (Invitrogen) ± test 
compounds including squalestatin (a gift from GlaxoSmithKline), squalene, arachidonyl trifluoromethyl 
ketone (AACOCF3), platelet-activating factor (PAF), 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-
(N,N,N-trimethyl)-hexanolamine (Hexa-PAF), methyl arachidonyl fluorophosphonate (MAFP), ginkgolide 
B, diethylumbelliferyl phosphate (DEUP), cholesteryl N-(2-dimethylaminoethyl) carbamate (Sigma) and 
the cells cultured for a further 3 days. Conditioned medium (CM) from these cells (7PA2-CM) was 
collected. To determine cell viability thiazolyl blue tetrazolium bromide was added to cells at a final 
concentration of 50 µM for 3 hours at 37oC. The supernatant was removed, the formazan product solubilized 
in 200 μl of dimethyl sulfoxide, transferred to an immunoassay plate and absorbance read at 595 nm. Cell 
survival was calculated with reference to untreated cells (100% survival). Cells were washed 3 times with 
ice cold PBS and then homogenised in an extraction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 
mM EDTA, 0.2% SDS) containing mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride, Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-46) and a phosphatase inhibitor cocktail 
(PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole (Sigma)) at 106 cells/ml. Cellular debris 
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was removed by centrifugation (20 minutes as 16000 x g). Both 7PA2-CM and cell extracts were 
centrifuged at 100,000 x g for 4 hours at 40C and passed through a 50 kDa filter (Sartorius). The CM from 
treated 7PA2 cells was then desalted (3 kDa filter, Sartorius to remove any residual drugs) and the retained 
material (> 3 kDa) diluted to its original volume. CM and cell extracts from non-transfected CHO cells 
(CHO-CM) were used as controls. 7PA2-CM containing Aβ monomers were prepared by filtration of 2 mls 
7PA2-CM through a 10 kDa filter (Sartorius). Oligomer preparations were the 7PA2-CM retained by the 
10 kDa filter diluted back to the original volume (2 mls).  
2.2. Soluble brain extracts – Were prepared from the temporal lobes of patients with a clinical, and 
pathologically-confirmed, diagnosis of Alzheimer’s disease using methods as described (10). Briefly, brain 
tissue was cut into pieces of approximately 100 mg and added to 2 ml tubes containing lysing matrix D 
beads (Q-Bio). PBS was added so that there was the equivalent of 100 mg brain tissue/ml. The tubes were 
shaken for 10 minutes (Disruptor genie, Scientific Instruments) to homogenize tissue. This process was 
performed 3 times before tubes were centrifuged at 16,000 x g for 10 minutes to remove cell debris. Soluble 
material was prepared by passage through a 50 kDa filter (Sartorius) (16,000 x g for 30 minutes) followed 
by desalting, retention by a 3 kDa filter (Sartorius) to eliminate bioactive small molecules and drugs. The 
retained material was collected (preparation contains peptides with molecular weights between 3 and 50 
kDa) and stored at -80oC. 
2.3. Western Blotting - For immunoblot analysis, 7PA2-CM/monomer or oligomer preparations were 
concentrated from 2000 to 100 µls using a 3 kDa filter (Sartorius). 10 µl of sample were mixed with an 
equal volume of in 0.5% NP-40, 5 mM CHAPS, 50 mM Tris, pH 7.4 and separated by electrophoresis on 
15% polyacrylamide gels. Proteins were transferred onto a Hybond-P polyvinylidene fluoride membrane 
by semi-dry blotting and blocked using 10% milk powder. Aβ was detected by incubation with mAb 6E10 
(Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and enhanced chemiluminescence.  
2.4. Aβ immunodepletions - To deplete preparations of Aβ they were incubated with 1 μg/ml mAb 4G8 
(reactive with amino acids 17-24 of Aβ, Covance) or 1 μg/ml mAb LN27 (reactive with amino acids 45 to 
53 of APP, (mock depletion)) and incubated on rollers for 2 hours. Protein G microbeads were added (10 
µl/ml) (Sigma) for 30 minutes and protein G bound-antibody complexes removed by centrifugation (1000 
x g for 5 minutes). 
2.5. Primary neuronal cultures - Cortical neurons were isolated from the brains of mouse embryos (day 
15.5) after mechanical dissociation and cell sieving as described (24). Cells were plated at 2 x 105 cells/well 
in 48 well plates in Hams F12 containing 5% foetal calf serum for 2 hours. Cultures were shaken (600 r.p.m 
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for 5 mins) and non-adherent cells removed by 2 washes in PBS. Neurons were subsequently grown in 
neurobasal medium containing B27 components and nerve growth factor (5 ng/ml) (Sigma) for 10 days. 
Immunohistochemistry showed that the cells were greater than 90% neurofilament positive. In experiments 
neurons were subsequently incubated with test compounds/Aβ preparations and synapse damage was 
assessed after 24 hours. All experiments were performed in accordance with European regulations 
(European Community Council Directive, 1986, 56/609/EEC) and approved by the local authority 
veterinary service/ethical committee. Neurons were washed 3 times in PBS and homogenised in an 
extraction buffer containing mixed protease and phosphatase inhibitors (as above) at 106 cells/ml. Nuclei 
and cell debris were removed by centrifugation (300 x g for 5 mins). To determine cell viability thiazolyl 
blue tetrazolium bromide was added to cells at a final concentration of 50 µM for 3 hours at 37oC. The 
supernatant was removed, the formazan product solubilized in 200 μl of dimethyl sulfoxide, transferred to 
an immunoassay plate and absorbance read at 595 nm. Neuronal survival was calculated with reference to 
untreated cells (100% survival). 
2.6. Isolation of Endoplasmic Reticulum – (ER) membranes – ER membranes were isolated from 7PA2 
cells using an ER preparation kit (Sigma) following the manufacturer’s instructions. Briefly, homogenised 
cell extracts were separated on a discontinuous density gradient (Opitiprep) and membranes containing ER 
components were identified with mAb reactive to the ER marker Grp 78 (Stressgen Biotechnology) (25). 
ER membranes were pre-treated ± drugs for 30 minutes and incubated with PAF for 1 hour. 
2.7. Synaptophysin ELISA - The amount of synaptophysin in neurons were measured by ELISA (26). 
Maxisorb immunoplates (Nunc) were coated with an anti-synaptophysin mouse mAb (MAB368-Millipore) 
was used as a capture antibody and bound synaptophysin was detected using rabbit polyclonal anti-
synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 
finally 1 mg/ml 4-nitrophenol phosphate (Sigma). Absorbance was measured on a microplate reader at 405 
nm. Samples were expressed as “units synaptophysin” where 100 units was defined as the amount of 
synaptophysin in control neurons. 
2.8. CSP ELISA – Maxisorb immunoplates were coated with a monoclonal antibody (mAb) to CSP ((sc-
136468) Santa Cruz) and blocked with 5% milk powder. Samples were added and bound CSP was detected 
using rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz) followed by a biotinylated anti-rabbit IgG, 
extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured 
at 405 nm. Samples were expressed as “units CSP” where 100 units was the amount of CSP in control 
neurons.  
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2.9. Cholesterol measurement - The concentrations of cholesterol in samples were measured using the 
Amplex Red cholesterol assay kit (Life Technologies) (27). Briefly, control and treated cell membranes 
were washed (16000 × g, 10 min) and lipids extracted by suspension in hexane:isopropanol (3:2, v/v) and 
disruption for 10 min in a cell disruptor ((Disruptor genie, Scientific Instruments). Samples were 
centrifuged (10,000 × g, 1 min), supernatants collected and dried under liquid nitrogen. Lipids were 
dissolved in 500 μl isopropanol:NP40 (9:1, v/v) and sonicated in a waterbath (30 minutes). Samples were 
pre-treated with catalase before the enzyme cocktail of the Amplex-red kit was added (0.1 M potassium 
phosphate buffer, pH 7.4; 0.25 M NaCl, 5 mM cholic acid, 0.1% Triton X-100, cholesterol oxidase, (± 
cholesterol esterase), horse radish peroxidase and 0.4 mM 10-acetyl-3,7-dihydroxyphenoxazine) were 
added and incubated at 37 °C for 30 minutes. Cholesterol is oxidised by cholesterol oxidase to yield 
hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxyphenoxazine 
(Amplex Red reagent) to produce highly fluorescent resorufin, which is measured by excitation at 530 nm 
and emission detection at 590 nm. Each experiment contained cholesterol standards and solvent only 
controls. Cholesterol concentrations of samples were calculated by reference to the cholesterol standards.  
2.10. Sample preparation for ELISA – To detach Aβ42 from membrane components that blocked specific 
epitopes samples (300 µl) were mixed with 700 µl of propan-2-ol and sonicated. Proteins were precipitated 
by adding 250 µls 100%w/v trichloroacetic acid, incubating on ice for 30 mins and centrifugation (16,000 
x g for 10 mins at 4oC). The pellet was washed twice with ice-cold acetone, suspended in a buffer containing 
150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% SDS and sonicated. 
2.11. Aβ42 ELISA – Nunc Maxisorb immunoplates were coated with an anti-Aβ mAb (4G8 - epitope 17-
24, Covance) in carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween and 
samples were applied for 1 hour. The detection antibody was an Aβ42 selective rabbit mAb BA3-9 
(Covance) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase (Sigma) and 1 
mg/ml 4-nitrophenol phosphate solution. Optical density was read in a spectrophotometer at 405 nm. 
 
2.12. Aβ40 ELISA - Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) and blocked with 
5% milk powder in PBS-tween. Samples were applied and Aβ40 was detected with rabbit polyclonal PC-
149 (Merck) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase. Total Aβ was 
visualised by addition of 4-nitrophenol phosphate and optical density was read in a spectrophotometer at 
405 nm. 
2.13. Statistical Analysis - Comparison of treatment effects was carried out using Student’s paired t-tests, 
one-way and two-way ANOVA with Bonferonni’s post hoc tests (IBM SPSS statistics 20). Error values are 
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standard deviation (SD) and significance was determined where p<0.01. Bivariate analysis using Pearson’s 
coefficient (IBM SPSS statistics 20) were used to examine correlations between data sets. 
3. Results 
 
3.1. CM from 7PA2 cells contains synaptotoxic Aβ - CM from 7PA2 cells caused the loss of synaptic 
proteins including synapsin-1, vesicle-associated membrane protein-1, CSP and synaptophysin from 
cultured neurons (26). Here we show that CM from 7PA2 cells, but not CM from CHO cells, reduced 
amounts of synaptophysin (Figure 1A) and CSP (Figure 1B) in cultured neurons indicative of synapse 
degeneration. The addition of 7PA2-CM did not reduce neuronal viability as measured by thiazolyl blue 
tetrazolium ((101% cell survival ± 6 compared with 100% ± 5, n=9, P=0.6) indicating that synapse 
degeneration occurred in the absence of any significant neuronal death. To demonstrate that it was Aβ 
within the CM that was responsible for the synaptotoxic effect, Aβ was removed following 
immunodepletion by mAb 4G8 (reactive with Aβ, epitope 17 to 24) (Figure 1C). Immunodepletion with 
mAb 4G8 reduced the concentrations of both Aβ40 and Aβ42 whereas mock-depletion had no significant 
effect (Table 1). The effects of 7PA2-CM on neuronal synaptophysin levels was removed by 
immunodepletion with mAb 4G8, but was unaffected by mock-depletion (Figure 1D) indicating that Aβ 
was the synaptotoxic component. As the 4G8 mAb used in these depletions reacts with an epitope common 
to several APP breakdown fragments including Aβ40 and Aβ42 and others (28) the current study does not 
identify the precise toxic entities. The effects of 7PA2-CM were than compared to that of soluble brain 
extracts derived from an Alzheimer’s patient (15). 7PA2-CM and soluble brain extracts containing similar 
concentrations of Aβ42 caused dose-dependent reductions in synaptophysin (Figure 1E) and CSP (Figure 
1F). 
 
3.2. Squalestatin reduced the amounts of synaptotoxic Aβ in CM – The effects of cholesterol depletion 
on the production of Aβ were examined after collecting CM from 7PA2 cells treated with 500 nM 
squalestatin, a squalene synthetase inhibitor (29). Squalestatin reduced the concentrations of cholesterol in 
7PA2 cells and the concentrations of Aβ42 and Aβ40 in CM, without affecting cell survival (Table 2). CM 
from 7PA2 cells treated with 500 nM squalestatin did not cause synapse damage (Figures 2A & B). This 
effect of squalestatin was dose-dependent (Figure 2C). The effects of squalestatin upon 7PA2 cells were 
reversed by the addition of 5 μM squalene; it increased cellular cholesterol concentrations and 
concentrations of Aβ40 and Aβ42 within CM (Table 2). Furthermore, CM from 7PA2 cells treated with a 
combination of 500 nM squalestatin and 5 μM squalene caused more synapse damage than CM from 7PA2 
cells treated with 500 nM squalestatin alone (Figure 2D). The addition of 5 μM squalene alone did not 
8 
 
affect the concentrations of cholesterol in 7PA2 cells, nor did it affect concentrations of Aβ40 and Aβ42 
found in CM.  
 
3.3. Squalestatin reduced the release of Aβ42 oligomers – Although the CM from squalestatin-treated 
cells contained significant concentrations of Aβ42 they did not cause synapse degeneration. To test the 
hypothesis that the synaptotoxicity of 7PA2-CM was relative to the concentration of Aβ oligomers, rather 
than the concentration of total Aβ, Aβ oligomers were isolated by filtration. Aβ oligomers were retained 
(and Aβ monomers removed from 7PA2-CM) by centrifugation with a 10 kDa filter; as shown by 
electrophoresis (Figure 3A). Treatment with squalestatin reduced the concentrations of Aβ42 oligomers in 
CM in a dose-dependent manner (Figure 3B). In 7PA2 cells treated with squalestatin (0.062 to 0.5 µM) 
there was a significant correlation between cholesterol concentrations of 7PA2 cells and the concentrations 
of Aβ42 oligomers released into CM, Pearson’s coefficient=0.71, p<0.01 (Figure 3C). An immunoblot 
showed that Aβ monomers were isolated from CM passed through a 10 kDa filter (Figure 3D). Treatment 
with squalestatin caused a dose-dependent increase in the concentrations of Aβ42 monomers in CM (Figure 
3E). There was a significant inverse correlation between the concentrations of Aβ42 oligomers and Aβ42 
monomers in CM from 7PA2 cells treated with squalestatin, Pearson’s coefficient = -0.79, p<0.01 (Figure 
3F). Greater than 90% of Aβ40 in the CM from control 7PA2 cells was monomeric and there were no major 
changes in the concentrations of Aβ40 monomers/oligomers in CM from squalestatin-treated cells (data not 
shown). As a consequence we focused upon measuring concentrations of Aβ42 monomers and oligomers in 
the following experiments. 
 
3.4. PLA2 inhibitors and PAF antagonists controlled the release of Aβ monomers and oligomers – 
Since PLA2 affects cholesterol distribution and cell trafficking (30,31) its role in Aβ42 production was also 
examined. CM from 7PA2 cells treated with cPLA2 inhibitors (1 µM AACOCF3 or 1 µM MAFP) did not 
cause synapse damage to cultured neurons (Figures 4A & B). The concentrations of Aβ42 oligomers were 
significantly reduced in CM from 7PA2 cells treated with 1 µM AACOCF3 or 1 µM MAFP (Table 3) when 
compared to CM from control cells. As the activation of cPLA2 results in the production of prostaglandins 
and PAF, specific inhibitors of these were tested. CM from 7PA2 cells treated with PAF antagonists (Hexa-
PAF or ginkgolide B) did not cause the loss of synaptophysin (Figure 4C) or CSP (Figure 4D) from neurons. 
The CM from 7PA2 cells treated with PAF antagonists contained lower concentrations of Aβ42 oligomers 
than CM from control cells (Table 3) and there was significant inverse correlation between the 
concentrations of Aβ42 oligomers and Aβ42 monomers in CM from 7PA2 cells treated with Hexa-PAF, 
Pearson’s coefficient= -0.89, p <0.01 (Figure 4E).  
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3.5. PAF reversed the effects of cPLA2 inhibitors on the release of Aβ monomers and oligomers – It 
was concluded that PAF, generated following activation of cPLA2, is involved in the production of Aβ. 
This hypothesis was supported by observations that the addition of 500 nM PAF reversed the effects of the 
cPLA2 inhibitor AACOCF3. Thus, CM from cells treated with AACOCF3 and PAF caused more synapse 
damage, as measured by the loss of synaptophysin (Figure 5A) and CSP (Figure 5B) than did CM from 
cells treated with AACOCF3 alone. Similarly, the addition of 500 nM PAF reversed the effects of 
AACOCF3 on the forms of Aβ released into CM; it reversed the AACOCF3-induced reduction in Aβ42 
oligomers (Figure 5C) and increase in Aβ42 monomers (Figure 5D).  
 
3.6 Squalene did not reverse the effects of a PAF antagonist - Since PAF antagonists had similar effects 
upon the release of Aβ as squalestatin, the hypothesis that PAF antagonists affected cholesterol synthesis 
was explored. However, in contrast to squalestatin, treatment of 7PA2 cells for 24 hours with 1 μM Hexa-
PAF did not significantly affect cellular cholesterol concentrations (0.69 μM cholesterol ± 0.09 compared 
with 0.7 μM ± 0.11, n=6, P=0.71). Furthermore, the addition of 5 μM squalene, which reversed the effects 
of squalestatin, did not reverse the effects of Hexa-PAF on 7PA2 cells.  Thus, CM from cells treated with 
a combination of 5 μM squalene and 1 μM H-PAF caused similar amounts of synapse damage, as measured 
by the loss of synaptophysin (Figure 6A) and CSP (Figure 6B), as CM from cells treated with 1 μM Hexa-
PAF alone. Similarly, the CM from cells treated with a combination of 5 μM squalene and 1 µM Hexa-
PAF contained similar concentration of Aβ42 oligomers (Figure 6C) and Aβ42 monomers (Figure 6D) as 
CM taken from cells treated with 1 μM Hexa-PAF alone. Collectively these results indicate that PAF 
antagonists were not acting like the cholesterol synthesis inhibitor squalestatin. 
3.7. PAF caused the release of cholesterol from cholesterol esters – A prior study had shown that PAF 
receptors were concentrated in membranes which also contained Grp78, a marker of the endoplasmic 
reticulum (ER) (32). The addition of PAF to ER membranes caused dose-dependent increases in cholesterol 
concentrations (Figure 7A) and reductions in concentrations of cholesterol esters (Figure 7B). There was a 
significant inverse correlation between concentrations of cholesterol and cholesterol esters in ER 
membranes incubated with PAF (0.125 to 1μM) (Figure 7C). The PAF-induced increase in cholesterol 
concentrations in these membranes was not affected by pre-treatment with 500 nM squalestatin indicating 
that PAF did not stimulate cholesterol synthesis (Figure 7D). The concentrations of cholesterol within cell 
membranes is partly controlled by the cholesterol ester cycle (33) and membrane cholesterol concentrations 
can be increased following activation of CEHs, enzymes that release cholesterol from cholesterol esters 
(34). Pre-treatment of ER membranes with 2 CEH inhibitors (diethylumbelliferyl phosphate (DEUP)) (35) 
and cholesteryl N-(2-dimethylaminoethyl) carbamate (36) inhibited both the PAF-induced increase in 
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cholesterol concentrations (Figure 7E) and the reduction in cholesterol ester concentrations (Figure 7F). 
We concluded that PAF altered cholesterol concentrations via its effects upon CEHs. 
3.8. CEH inhibitors reduced the release of synaptotoxic Aβ - Treatment of 7PA2 cells with CEH 
inhibitors (DEUP or cholesteryl N-(2-dimethylaminoethyl) carbamate) caused a dose-dependent reduction 
in the concentrations of Aβ42 oligomers (Figure 8A) and an increase in Aβ42 monomers (Figure 8B) found 
within CM. There were significant inverse correlations between concentrations of Aβ42 oligomers and Aβ42 
monomers in CM from 7PA2 cells treated with DEUP, Pearson’s coefficient= -0.92, p<0.01 or cholesteryl 
N-(2-dimethylaminoethyl) carbamate, Pearson’s coefficient= -0.72, p<0.01 (Figure 8C). An immunoblot 
showed that CM from DEUP-treated cells contained more Aβ monomers and less Aβ oligomers than CM 
from control cells (Figure 8D). CM from 7PA2 cell treated with either 20 µM DEUP or 5 μM cholesteryl 
N-(2-dimethylaminoethyl) carbamate did not cause the loss of synaptophysin (Figure 8E) or CSP (Figure 
8F) from neurons. Collectively these results are consistent with the hypothesis that CEHs affect cellular 
cholesterol concentrations that regulate the release of the Aβ oligomers that cause synapse damage. 
3.9. CEH inhibitors did not have a direct effect upon Aβ42 oligomers - These results raised the possibility 
that drugs may interact directly with Aβ oligomers within the CM causing them to dissociate into 
monomers. This hypothesis was tested by incubating Aβ preparations with 500 nM squalestatin, 1 μM 
Hexa-PAF or 20 μM DEUP at 37oC for 3 days. An immunoblot showed that there were no significant 
differences in the amounts of Aβ oligomers and monomers between control and treated preparations (Figure 
9). In another experiment Aβ oligomer preparations (containing 10 nM Aβ42) were incubated with 500 nM 
squalestatin, 1 μM Hexa-PAF or 20 μM DEUP at 37oC for 3 days. When these preparations were passed 
through a 10 kDa filter, monomeric forms of Aβ42 were not detected indicating that these drugs had not 
caused the dissociation of Aβ42 oligomers. 
3.10. CEH inhibitors reduced cell-associated Aβ42 oligomers - The possibility that the drugs tested 
simply affected the release, rather than the production of Aβ was examined by measuring Aβ in cell extracts 
from treated 7PA2 cells. The concentrations of Aβ42 oligomers in 7PA2 cell extracts were significantly 
reduced by treatment with 500 nM squalestatin, 1 µM AACOCF3, 1 µM MAFP, 1 µM Hexa-PAF, 1 µM 
ginkgolide B, 1 µM DEUP or 20 µM cholesteryl N-(2-dimethylaminoethyl) carbamate (Table 4). Treatment 
with these drugs also increased the amounts of cell-associated Aβ42 monomers. 
3.11. CM from treated 7PA2 cells protected neurons against Aβ oligomer-induced synapse damage – 
The CM from 7PA2 cells treated with squalestatin, PAF antagonists or CEH inhibitors contained high 
concentrations of Aβ monomers which have been reported to have neuroprotective properties (23). Here we 
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mixed CM from 7PA2 cells treated with either 500 nM squalestatin, 1 μM Hexa-PAF or 20 μM DEUP with 
either soluble brain extracts or phospholipase A2-activating peptide (PLAP). Both the soluble brain extracts 
and PLAP caused the loss of synaptophysin and CSP from neuronal cultures. The presence CM from 7PA2 
cells treated with squalestatin, PAF antagonists or CEH inhibitors protected neurons against the brain 
extract-induced reduction in synaptophysin (Figure 10A). CM from treated CHO cells did not affect the 
brain extract-induced reduction in synaptophysin (data not shown). The protective effects of CM from 
treated 7PA2 cells were stimulus specific; they did not affect the loss of synaptophysin caused by PLAP 
(Figure 10B). CM from DEUP-treated 7PA2 cells was examined in more detail. Immunodepletion with the 
Aβ-specific mAb 4G8 removed the inhibitory factor from CM (Figure 10C) indicating that the protective 
component was Aβ. Monomer preparations derived from CM from DEUP-treated 7PA2 cells also protected 
neurons against the brain extract-induced loss of synaptophysin. Finally, Aβ monomers derived from CM 
from DEUP-treated 7PA2 cells had a dose-dependent effect against the loss of synaptophysin caused by a 
brain extract containing 2 nM Aβ42 (Figure 10D). We note that in addition to Aβ40 and Aβ42 there are likely 
to be other APP fragments in the monomer preparations and that these may contribute to the activity seen 
here. 
 
4. Discussion 
 
Although many studies have examined the factors that affect Aβ production this is the first study that we 
are aware of that differentiated between toxic and non-toxic forms of Aβ. The release of biologically active 
forms of Aβ by 7PA2 cells was examined using synapse damage in cultured neurons as a model. The 
synapse damage caused by 7PA2-CM was comparable to that caused by soluble brain extracts from AD 
patients when standardized on their Aβ42 content. In addition, the synapse damage caused by both 7PA2-
CM and brain extracts (15) were Aβ-dependent, suggesting that 7PA2 cells release synaptotoxic forms of 
Aβ similar to the Aβ oligomers found in brains of AD patients. The 2 key findings of this study were firstly, 
that the release of synaptotoxic Aβ oligomers is controlled by pathways sensitive to squalestatin, PLA2 
inhibitors, PAF antagonists and CEH inhibitors. All these compounds affected either cholesterol 
concentrations or cholesterol distribution within cell membranes. Secondly, that treated cells released 
increased concentrations of Aβ monomers and that these monomeric forms of Aβ protected neurons against 
the synaptotoxic Aβ oligomers.  
 
Our observation that squalestatin caused only small differences in the production of Aβ40 and Aβ42 was in 
contrast to prior reports of the effects of other cholesterol synthesis inhibitors. This may be due to using 
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squalestatin, a more specific cholesterol synthesis inhibitor that does not affect isoprenoid function (22), 
rather than conventional “statins” used in other reports. Furthermore, the reduction in cellular cholesterol 
concentrations in these studies was mild when compared to other studies (19,37). The key observation, that 
CM from squalestatin-treated cells contained Aβ42 but did not cause synapse damage, showed that 
measuring concentrations of Aβ alone was a poor indicator of biological activity. That squalestatin 
selectively affected the production of soluble Aβ oligomers, thought to be major causes of synapse damage 
in AD (10,16,38), is consistent with a report that reduced cholesterol synthesis did not affect Aβ production 
but did extend lifespan in a mouse model of AD (39). Cholesterol affects the formation and function of 
lipid rafts (40,41) in which APP and many of the enzymes involved in the generation of Aβ are found (42-
44). Consequently, it seems likely that the squalestatin-induced reduction in cholesterol concentrations 
would affect the processing of APP to Aβ oligomers.  
 
Cholesterol concentrations within the ER were increased after activation of cPLA2 (25). This enzyme 
affects tubule formation and consequently intracellular trafficking of proteins (31), specifically within the 
trans-golgi network (45), a key area of APP metabolism (46). Here we show that inhibition of cPLA2 in 
7PA2 cells resulted in CM that did not cause synapse damage. Activation of cPLA2 leads to the production 
of PAF and PAF antagonists also reduced the release of Aβ oligomers from 7PA2 cells. As the addition of 
PAF reversed the effects of cPLA2 inhibitors we concluded that it was the key mediator involved in this 
pathway. 7PA2 cells treated with cPLA2 inhibitors or PAF antagonists, like cells treated with squalestatin, 
released less Aβ42 oligomers and more Aβ42 monomers. 
 
In contrast to squalestatin, neither cPLA2 inhibitors, nor PAF antagonists, had a significant effect on 7PA2 
cellular cholesterol concentrations, and their effects upon Aβ production were not reversed by squalene 
indicating that they did not affect cholesterol synthesis. However, it could be argued that Aβ production 
might be affected by small changes in cholesterol concentrations in specific organelles which would not be 
seen in total cell membrane extracts. PAF receptors were concentrated in the ER and PAF increased 
cholesterol concentrations within isolated ER membranes. The cholesterol concentrations in cell 
membranes are controlled by the cholesterol ester cycle (47) and lipid droplets, containing high 
concentrations of cholesterol esters are concentrated in the ER (48). The PAF-induced increase in 
cholesterol in ER membranes was accompanied by a reduction in cholesterol esters; there was an inverse 
correlation between concentrations of cholesterol and cholesterol esters, leading to the conclusion PAF 
activates CEHs. The inhibition of PAF-induced changes by CEH inhibitors supported this hypothesis. 
Notably CM from 7PA2 cells treated with CEH inhibitors were similar to CM from 7PA2 cells treated with 
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PAF antagonists; they contained less Aβ42 oligomers, more Aβ42 monomers and did not cause synapse 
damage.  
 
Each class of drug tested, squalestatin, PAF antagonists or CEH inhibitors demonstrated an increased 
release of Aβ42 monomers that closely correlated with the reduction in Aβ42 oligomers. A key finding was 
that CM from cells treated with either squalestatin, a PAF antagonist or a CEH inhibitor reduced synapse 
damage caused by soluble Aβ derived from a brain extract. The neuroprotective effect was mediated by Aβ 
monomer preparations, consistent with reports that Aβ monomers are neuroprotective (23). It is noteworthy 
that thee Aβ monomer preparations may contain other APP fragments in addition to Aβ40 and Aβ42 peptides 
as has been reported in cerebrospinal fluid (49). Critically these results suggest that synapse damage is 
dependent upon the ratio of Aβ monomers and Aβ oligomers, rather than the total Aβ concentration. We 
can only speculate how squalestatin, PLA2 inhibitors, PAF antagonists and CEH inhibitors alter APP 
metabolism and subsequently the release of Aβ monomers/oligomers. All of the drugs affected cholesterol 
concentrations which is important for the formation and function of lipid rafts (41). APP and many of the 
enzymes involved in the generation of Aβ are found in lipid rafts (42,43) and Aβ42 is produced within 
cholesterol-sensitive lipid rafts (50). Protein cargos in lipid rafts traffic via different pathways to those in 
the normal cell membrane (51) and consequently APP in lipid rafts may be targeted to different cell 
compartments (and consequently interacts with different enzymes) than APP found in the normal cell 
membrane. In addition, membrane cholesterol concentrations affect the process of exocytosis (52) and may 
alter the release of Aβ from cells. The possibility that changes in the concentrations of Aβ42 
oligomers/monomers within cell supernatants was mediated by cholesterol-sensitive changes in the release 
of Aβ monomers/oligomers alone  appears unlikely as these drugs also reduced concentrations of Aβ42 
oligomers and increased Aβ42 monomers in cell extracts.  
 
5. Conclusions 
 
In conclusion these results indicate that in 7PA2 cells the production of synaptotoxic and neuroprotective 
forms of Aβ can be modified by pharmacological manipulation. More specifically, the Aβ 
monomer:oligomer ratio was sensitive to drugs that altered cholesterol concentrations in cell membranes. 
Furthermore this study demonstrates the need to understand the biological activity of the forms of Aβ 
measured.  
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7. Tables 
 
 Aβ40   (nM) Aβ42  (nM) 
Control 7PA2-CM 7.42 ± 0.6 2.21 ± 0.3 
Aβ-depleted 7PA2-CM 0.67 ± 0.28* 0.04 ± 0.04* 
Mock depleted 7PA2-CM 6.95 ± 0.81 2.03 ± 0.21 
 
Table 1. Immunodepletion reduces Aβ concentrations in 7PA2-CM - The concentrations of Aβ40 and 
Aβ42 in control 7PA2-CM and the same 7PA2-CM after immunodepletion with the Aβ-reactive mAb 4G8, 
or after mock depletion (incubation with mAb LN27 reactive with APP but not Aβ). Values are means ± 
SD from triplicate experiments performed 3 times (n=9). *=concentrations of Aβ40/Aβ42 significantly less 
than in untreated 7PA2-CM, p<0.01. 
 
 
Treatment Cell viability (%) Cholesterol (μM) Aβ42 (nM) Aβ40 (nM) 
Control 100 ± 4 0.65 ± 0.05 2.44 ± 0.29 7.12 ± 0.45 
Squalestatin 98 ± 6 0.51 ± 0.04* 1.68 ± 0.24* 5.34 ± 0.48* 
Squalene 101 ± 5 0.65 ± 0.06* 2.51 ± 0.31 7.28 ± 0.41 
Squalestatin + squalene 99 ± 4 0.66 ± 0.05 2.37 ± 0.34 7.06 ± 0.33 
 
 
Table 2 – Squalene reversed the effects of squalestatin on 7PA2 cells – The survival of 7PA2 cells, the 
concentrations of cholesterol in 7PA2 cells and the concentrations of Aβ42 and Aβ40 in CM from 7PA2 cells 
treated for 3 days with control medium, 500 nM squalestatin, 5 µM squalene or a combination of both. 
Values are means ± SD from triplicate experiments performed 3 times (n=9). *=concentrations significantly 
less than in control cells, p<0.01.  
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 Aβ42  oligomers (nM) 
Control cells 2.13 ± 0.31 
1 µM AACOCF3 0.38 ± 0.28* 
1 µM MAFP 0.74 ± 0.23* 
1 µM Hexa-PAF 0.28 ± 0.24* 
1 µM ginkgolide B 0.36 ± 0.19* 
 
Table 3. Treatment of 7PA2 cells with PLA2 inhibitors or PAF antagonists reduced concentrations of 
Aβ42 oligomers in CM - The concentrations of Aβ42 oligomers in CM from 7PA2 cells treated with 
squalestatin, cPLA2 inhibitors (AACOCF3 or MAFP) or PAF antagonists (Hexa-PAF or ginkgolide B) or 
CEH inhibitors (DEUP or  cholesteryl N-(2-dimethylaminoethyl) carbamate). Values are means ± SD from 
three experiments measured in triplicate, n=9. *= concentrations of Aβ42 oligomers significantly less than 
in control cells, p<0.01. 
 
 7PA2-cells 
Treatment Aβ42 oligomers (nM) Aβ42 monomers (nM) 
Control 12.47 ± 0.1.2 0.93 ± 0.33 
Squalestatin 8.59 ± 0.89* 1.2 ± 0.15* 
AACOCF3 9.17 ± 0.71* 1.09 ± 0.1 
MAFP 9.13 ± 0.98* 1.11 ± 0.13 
Hexa-PAF 9.01 ± 0.99* 1.12 ± 0.12* 
Ginkgolide B 8.89 ± 1.04* 1.18 ± 0.19 
DEUP 8.51± 0.84* 1.28 ± 0.12* 
Cholesteryl-carbamate 8.53 ± 1.1* 1.25 ± 0.1* 
 
 
Table 4 – Squalestatin, PLA2 inhibitors, PAF antagonists or CEH inhibitors reduced concentrations 
of cell-associated Aβ42 oligomers – The concentrations of Aβ42 oligomers and Aβ42 monomers in cell 
extracts from 7PA2 cells treated with control medium, 500 nM squalestatin, 1µM AACOCF3, 1µM MAFP, 
1µM Hexa-PAF, 1µM ginkgolide B, 20 µM DEUP or 5 µM cholesteryl N-(2-dimethylaminoethyl) 
carbamate for 3 days. Values are means ± SD from triplicate experiments performed 3 times, n=9. 
*=concentrations significantly different from controls, p<0.01. 
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8. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 7PA2 cells release synaptotoxic Aβ - The amounts of synaptophysin (A) and CSP (B) in neurons 
incubated with CM from 7PA2 cells (■) or CHO cells (□). Values are means ± SD from triplicate 
experiments performed 3 times, n=9. *=amounts of synaptophysin/CSP significantly less than in neurons 
incubated with CHO-CM. (C) Immunoblot showing Aβ monomers (M), dimers (D) and trimers (T) in 
7PA2-CM (1) and Aβ-depleted 7PA2-CM (2). (D) The amounts of synaptophysin in neurons incubated 
with CM from CHO cells, 7PA2-CM, Aβ-depleted 7PA2-CM or mock-depleted 7PA2-CM as shown. 
Values are means ± SD from triplicate experiments performed 3 times, n=9. *=amounts of synaptophysin 
significantly higher than in neurons incubated with 7PA2-CM. The amounts of synaptophysin (E) and CSP 
(F) in neurons incubated with 7PA2-CM (●) or soluble brain extract (○) containing Aβ42 as shown. Values 
are means ± SD from triplicate experiments performed 3 times, n=9.  
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Figure 2. Squalestatin reduced the release of synaptotoxic Aβ - The amounts of synaptophysin (A) and 
CSP (B) in neurons incubated with CM from 7PA2 cells treated with control medium (□) or 500 nM 
squalestatin (ST) (■). Values are means ± SD from triplicate experiments performed 3 times, n=9. 
*=amounts of synaptophysin/CSP significantly higher than in neurons incubated with control 7PA2-CM.  
(C) The amounts of synaptophysin in neurons incubated with CM from 7PA2 cells treated with control 
medium or squalestatin as shown. Values are means ± SD from triplicate experiments performed 3 times, 
n=9. *=amounts of synaptophysin significantly higher than in neurons incubated with CM from control 
cells, P<0.01. (D) The amounts of synaptophysin in neurons incubated with CM from 7PA2 cells treated 
with control medium, 500 nM squalestatin (ST), 5 μM squalene (SQ) or a combination of 5 μM squalene 
and 500 nM squalestatin as shown. Values are means ± SD from triplicate experiments performed 3 times, 
n=9. *=synaptophysin significantly less than in neurons incubated with CM from 7PA2 cells treated with 
squalestatin (ST). 
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Figure 3. Squalestatin altered the release of Aβ42 oligomers and Aβ42 monomers (A) Immunoblot 
showing forms of Aβ monomers (M), dimers (D) and trimers (T)) in 7PA2-CM (1) and 7PA2-CM oligomer 
preparations (>10 kDa) (2). (B) The concentrations of Aβ42 oligomers in CM from 7PA2 cells treated with 
control medium or squalestatin as shown. Values are means ± SD from triplicate experiments performed 3 
times, n=9. *=concentrations of Aβ42 oligomers significantly less than in control 7PA2-CM, p<0.01. (C) 
There was a  significant correlation between concentrations of cholesterol in 7PA2 cells treated with 
squalestatin (0.062 to 0.5 µM) and concentrations of Aβ42 oligomers in CM, Pearson’s coefficient=0.71, 
p<0.01. (D) Immunoblot showing Aβ monomers, dimers and trimers in 7PA2-CM (1) and in monomer 
preparations (7PA2-CM passed through a 10 kDa filter) (2). (E) The concentrations of Aβ42 monomers in 
CM from 7PA2 cells treated with control medium or squalestatin as shown. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. *=concentrations of Aβ42 monomers significantly higher 
than in control CM. (F) There was a significant inverse correlation between concentrations of Aβ42 
oligomers and Aβ42 monomers in CM from 7PA2 cells treated with squalestatin (0.062 to 0.5 µM), 
Pearson’s coefficient = -0.79, p<0.01.   
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Figure 4. PLA2 inhibitors and PAF antagonists reduced the release of synaptotoxic Aβ - The amounts 
of synaptophysin (A) and CSP (B) in neurons incubated with CM from 7PA2 cells treated with control 
medium or cPLA2 inhibitors (1 μM MAFP or 1 μM AACOCF3). Values are means ± SD from triplicate 
experiments performed 3 times, n=9. The amounts of synaptophysin (C) and CSP (D) in neurons incubated 
with CM from 7PA2 cells treated with control medium, PAF antagonists (1 μM Hexa-PAF or 1 µM 
ginkgolide B) or cyclooxygenase inhibitors (2 μM aspirin or 5 μM ibuprofen) as shown. Values are means 
± SD from triplicate experiments performed 3 times, n=9. *=synaptophysin/CSP significantly higher than 
in neurons incubated with CM from control cells. (E) There was a significant inverse correlation between 
the concentrations of Aβ42 oligomers and Aβ42 monomers in CM from 7PA2 cells treated with Hexa-PAF 
(.125 to 1 μM), Pearson’s coefficient= -0.89, p <0.01.   
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Figure 5. PAF reversed the effects of a PLA2 
inhibitor on the release of synaptotoxic Aβ – The 
amounts of synaptophysin (A) and CSP (B) in 
neurons incubated with CM from 7PA2 cells 
treated with control medium, 1 μM AACOCF3, 
500 nM PAF or a combination of  1 μM AACOCF3 
and 500 nM PAF as shown. Values are means ± 
SD from triplicate experiments performed 3 times, 
n=9. *=concentrations of synaptophysin/CSP 
significantly less than those of neurons incubated 
with CM from AACOCF3-treated cells. The 
concentrations of Aβ42 oligomers (C) and Aβ42 
monomers (D) in CM from 7PA2 cells treated with control medium,1 μM AACOCF3, 500 nM PAF or a 
combination of  1 μM AACOCF3 and 500 nM PAF as shown. Values are mean Aβ42 ± SD from triplicate 
experiments performed 3 times, n=9. *=concentrations of Aβ42 oligomers/monomers significantly different 
to those in CM from AACOCF3-treated cells.  
 
 
Figure 6. Squalene did not reverse the effects of a 
PAF antagonist on the release of synaptotoxic Aβ – 
The amounts of synaptophysin (A) and CSP (B) in 
neurons incubated with CM from 7PA2 cells treated 
with either control medium, 1 μM Hexa-PAF, 5 μM 
squalene or a combination of 1 μM Hexa-PAF and 5 
μM squalene as shown. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. 
*=concentrations of synaptophysin/CSP not 
significantly different from those of neurons incubated 
with CM from H-PAF-treated cells. The amounts of 
Aβ42 oligomers (C) and Aβ42 monomers (D) in CM from 7PA2 cells treated with either control medium, 1 
μM Hexa-PAF, 5 μM squalene or a combination of 1 μM Hexa-PAF and 5 μM squalene as shown. Values 
are means ± SD from triplicate experiments performed 3 times, n=9. *=concentrations of Aβ42 
oligomers/monomers not significantly different from those in CM from H-PAF-treated cells.  
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Figure 7. PAF increased cholesterol concentrations in ER membranes – The concentrations of 
cholesterol (A) and cholesterol esters (B) in ER membranes treated with control medium or PAF as shown. 
Values are means ± SD from triplicate experiments performed twice, n=6.*=concentrations of 
cholesterol/cholesterol esters significantly different to controls. (C) There was a significant inverse 
correlation between the concentrations of cholesterol and cholesterol esters in ER membranes incubated 
with PAF (0.125 to 1 µM), Pearson’s coefficient = -0.78, p <0.01. (D) The concentrations of cholesterol in 
ER membranes incubated with either control medium, 1 µM PAF, 500 nM squalestatin (ST) or pre-treated 
with 500 nM ST and incubated with 1 µM PAF as shown. Values are mean cholesterol concentrations ± 
SD from triplicate experiments performed 3 times, n=9. *=concentrations of cholesterol significantly higher 
than those in control ER membranes. The concentrations of cholesterol (E) and cholesterol esters (F) in ER 
membranes pre-treated with control medium, 20 μM DEUP or 5 µM cholesteryl carbamate as shown and 
then incubated with control medium (□) or 1 µM PAF (striped bars). Values are means ± SD from triplicate 
experiments performed 3 times, n=9. *=concentrations of cholesterol/cholesterol esters significantly 
different to those in ER membranes incubated with PAF alone.  
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Figure 8. CEH inhibitors reduced the release of synaptotoxic Aβ– The concentrations of Aβ42 oligomers 
(A) and Aβ42 monomers (B) in CM from 7PA2 cells treated with either DEUP () or cholesteryl N-(2-
dimethylaminoethyl) carbamate (▼) as shown. Values are means ± SD from triplicate experiments 
performed 3 times, n=9. (C) There was a significant inverse correlation between the concentrations of Aβ42 
oligomers and Aβ42 monomers in CM from 7PA2 cells incubated with DEUP (), Pearson’s coefficient = 
-0.92, p<0.01 or cholesteryl N-(2-dimethylaminoethyl) carbamate (▼), Pearson’s coefficient = -0.71, 
p<0.01. (D) Immunoblot showing forms of Aβ in CM from (1) control 7PA2 cells and (2) DEUP-treated 
7PA2-cells.The amounts of synaptophysin (E) and CSP (F) in neurons incubated with CM from 7PA2 cells 
treated with control medium or with CEH inhibitors (5 µM DEUP or 20 µM cholesteryl N-(2-
dimethylaminoethyl) carbamate as shown. Values are means ± SD from triplicate experiments performed 
3 times, n=9. *=amounts of synaptophysin/CSP significantly higher than in neurons incubated with control 
7PA2-CM.   
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Figure 9 – Drugs do not cause the dissociation of 
Aβ oligomers - Immunoblot showing forms of Aβ in 
CM from 7PA2 cells incubated for 3 days at 37oC 
with (1) control medium, (2) 500 nM squalestatin, (3) 
1 μM Hexa-PAF or (4) 20 µM DEUP. 
 
 
 
 
 
Figure 10. CM from DEUP-treated 7PA2 cells 
protected neurons against Aβ-induced synapse 
damage – The amounts of synaptophysin in neurons 
incubated with 2 nM Aβ42 (A) or 250 nM PLAP (B) mixed 
with CM from CHO cells or CM from 7PA2 cells treated 
with 1 µM squalestatin, 1 µM Hexa-PAF or 20 µM DEUP 
as shown. Values are means ± SD from triplicate 
experiments performed 3 times, n=9. *=amounts of 
synaptophysin significantly greater than in neurons 
incubated with Aβ oligomers and CHO-CM. (C) The 
amounts of synaptophysin in neurons incubated with 2 nM 
Aβ42 mixed with CM from CHO cells, CM from DEUP-
treated 7PA2 cells, or CM from DEUP-treated 7PA2 cells 
depleted of Aβ or mock-depleted or monomer 
preparations derived from CM from DEUP-treated 7PA2 
cells as shown. Values are means ± SD from triplicate 
experiments performed 3 times (n=9). *=amounts of 
synaptophysin significantly greater than in neurons 
incubated with Aβ oligomers and CHO-CM. (D) The 
amounts of synaptophysin in neurons pre-treated with Aβ 
monomers derived from DEUP-treated 7PA2 cells (containing Aβ42 monomers as shown) and incubated 
with soluble brain extract containing 2 nM Aβ42.  Values are means ± SD from triplicate experiments 
performed 3 times, n=9. 
